Tpoxx, Tecovirimat siga(tecovirimat)
Tecovirimat Monohydrate, Tpoxx (tecovirimat) is a small molecule pharmaceutical. Tecovirimat was first approved as Tpoxx on 2018-07-13. It is used to treat smallpox in the USA. It has been approved in Europe to treat cowpox, mpox (monkeypox), poxviridae infections, smallpox, and vaccinia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| animal diseases | D000820 |
Trade Name
FDA
EMA
Tpoxx
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tecovirimat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TPOXX | SIGA Technologies | N-208627 RX | 2018-07-13 | 1 products, RLD, RS |
| TPOXX | SIGA Technologies | N-214518 RX | 2022-05-18 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tpoxx | New Drug Application | 2024-07-03 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TECOVIRIMAT, TPOXX, SIGA TECHNOLOGIES | |||
| 2025-07-13 | ODE-200 | ||
Patent Expiration
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Virus diseases | D014777 | — | B34 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Orthopoxvirus | D018155 | — | — | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Vaccinia | D014615 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Poxviridae infections | D011213 | EFO_0007370 | B08.04 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tecovirimat |
| INN | tecovirimat |
| Description | Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and mpox. In 2018 it became the first antipoxviral drug approved in the United States.
|
| Classification | Small molecule |
| Drug class | antivirals: antiviral, disrupts viral maturation |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NN1C(=O)[C@H]2[C@H]3C=C[C@H]([C@@H]4C[C@H]34)[C@H]2C1=O)c1ccc(C(F)(F)F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 816458-31-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1257073 |
| ChEBI ID | — |
| PubChem CID | 16124688 |
| DrugBank | DB12020 |
| UNII ID | F925RR824R (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,539 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
102 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use